ArticleCancer research and treatment2018
Low-Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-Cell Lymphoma.
Article in Cancer research and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum.Blood advances · 2020Trial
- Long-term clinical outcomes of patients with localized primary ocular adnexal mucosa-associated lymphoid tissue lymphoma.International journal of hematology · 2026Article
- Clinical Outcomes and Safety of Ultra-Low-Dose Radiotherapy for Ocular Adnexal Lymphoma: A Systematic Review.Cancers · 2025Review
- Review
- Incidence, clinical features, and survival outcomes of primary malignant conjunctival tumor: a US population-based retrospective cohort analysis based on the SEER database (1975-2018).Translational cancer research · 2025Article
- Conjunctival Lymphoma.Eye (London, England) · 2023Review
- [Treatment and prognosis of primary ocular adnexal extranodal marginal zone mucosa-associated lymphoid tissue lymphoma: a report from a single center].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Ultra-low dose external beam radiotherapy for presumed choroidal lymphoma: a case report.Journal of ophthalmic inflammation and infection · 2022Article
- Iatrogenic Ocular Surface Diseases Occurring during and/or after Different Treatments for Ocular Tumours.Cancers · 2021Review
- Radiotherapy of extranodal low-grade follicular and marginal zone lymphomas: long-term follow-up of 159 patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020Article
- Classification, diagnosis, and management of conjunctival lymphoma.Eye and vision (London, England) · 2019Review
- Apigenin and Exposure to Low Dose Gamma Radiation Ameliorate Acetic Acid-Induced Ulcerative Colitis in Rats.Dose-response : a publication of International Hormesis SocietyArticle
- Necrotizing Fasciitis: Low-Dose Radiotherapy as a Potential Adjunct Treatment.Dose-response : a publication of International Hormesis SocietyReview
- Conjunctival lymphoma: case report.Romanian journal of ophthalmologyArticle
- Health Impacts of Low-Dose Ionizing Radiation: Current Scientific Debates and Regulatory Issues.Dose-response : a publication of International Hormesis SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to evaluate the clinical features and the long-term outcomes of primary conjunctival marginal zone B-cell lymphoma (MZBCL) patients who were treated with radiation therapy (RT). MATERIALS AND
methodsRetrospective data of 79 patients with 121 primary conjunctival MZBCL lesions were collected from January 1, 2001 till June 30, 2014. All lesions were treated by local RT (26 Gy) with patient-specific customized lens-shielding device.
resultsThe current Korean patients' cohort showed younger median age at diagnosis (38 years), great female preponderance (78.5%) and more frequent bilateral involvement (53.2%) than the previous studies. Following 26 Gy's RT, excellent clinical outcomes were achieved: 5-year rates of overall survival, local relapse-free survival, and contralateral relapse-free survival were 100%, 98.1%, and 91.5%, respectively. Two patients (2.5%) developed local relapse and five (6.3%) developed relapse at initially uninvolved contralateral conjunctiva with median interval of 52.9 months, and late adverse events of grade 2 and 3 occurred in seven (8.8%) and two (2.5%) patients, respectively.
conclusion26 Gy's RT was highly effective and safe, with the use of lens-shielding device, in treating patients with primary conjunctival MZBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.